Product logins

Find logins to all Clarivate products below.


Chronic Sinusitis | Treatment Algorithms: Claims Data Analysis | US | 2020

Chronic sinusitis is prolonged inflammation of the paranasal sinuses that persists for more than 12 weeks despite treatment. Intranasal corticosteroids are typically used for treatment, followed by antibiotics or allergy medications, such as antihistamines, decongestants, leukotriene inhibitors, and anti-inflammatory agents. Although chronic sinusitis is one of the more-prevalent chronic illnesses in the United States, not many treatment options are available. Because no antibiotics are currently approved by the FDA to treat chronic sinusitis, otolaryngologists often prescribe antibiotics off-label based primarily on historical practice.

The report answers key questions including:

  • What patient shares do key therapies and brands garner by line of therapy in newly diagnosed chronic sinusitis patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed chronic sinusitis patients?
  • How has the amoxicillin-clavulanate combination been integrated into the treatment algorithm, and what is its source of business?
  • What percentage of chronic sinusitis patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
  • What percentage of chronic sinusitis patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
  • What are the product-level compliance and persistency rates among drug-treated patients?

Treatment Algorithms Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Related Market Assessment Reports

Report
Alzheimer’s Disease – Current Treatment – Treatment Algorithms: Claims Data Analysis – Alzheimer’s Disease (US)
The treatment of early Alzheimer’s disease (AD) is being transformed by the launches of Eisai / Biogen’s lecanemab (Leqembi) and Eli Lilly’s donanemab (Kisunla), and additional disease-…
Report
Psoriasis – Access & Reimbursement – Access & Reimbursement – Psoriasis (US)
The U.S. psoriasis treatment landscape is rapidly evolving, with newer, more effective therapies increasing competition for favorable MCO coverage, further intensified by the introduction of…
Report
Parkinson’s Disease – Current Treatment – Treatment Algorithms: Claims Data Analysis – Parkinson’s Disease (US)
Parkinson’s disease (PD) is a progressive neurodegenerative condition that is treated chronically with prescription therapies from an array of mechanistically distinct drug classes, including…
Report
Attention-Deficit-Hyperactivity Disorder – Current Treatment – Treatment Algorithms: Claims Data Analysis – Pediatric ADHD (US)
ADHD is a common pediatric neurodevelopmental disorder, with diagnosis rates supported by increased awareness and routine screening; however, symptoms often persist into adulthood. Longacting…
Report
GLP-1 receptor agonists – Current Treatment – Current Treatment: Physician Insights – GLP-1 Receptor Agonist Products (US)
Glucagon-like peptide-1 receptor agonist (GLP-1 RA) products like Novo Nordisk’s SC semaglutide (Ozempic / Wegovy) and Eli Lilly’s tirzepatide (Mounjaro / Zepbound) have seen significant growth…